Ascendis Pharma A/S (ASND)
NASDAQ: ASND · Real-Time Price · USD
240.00
+1.34 (0.56%)
May 11, 2026, 10:58 AM EDT - Market open
Ascendis Pharma Revenue
Ascendis Pharma had revenue of 246.60M EUR in the quarter ending March 31, 2026, with 144.27% growth. This brings the company's revenue in the last twelve months to 865.78M, up 134.82% year-over-year. In the year 2025, Ascendis Pharma had annual revenue of 720.13M with 98.03% growth.
Revenue (ttm)
865.78M EUR
Revenue Growth
+134.82%
P/S Ratio
14.85
Revenue / Employee
728,158 EUR
Employees
1,189
Market Cap
14.91B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 720.13M | 356.49M | 98.03% |
| Dec 31, 2024 | 363.64M | 96.92M | 36.34% |
| Dec 31, 2023 | 266.72M | 215.54M | 421.20% |
| Dec 31, 2022 | 51.17M | 43.40M | 557.93% |
| Dec 31, 2021 | 7.78M | 825.00K | 11.87% |
| Dec 31, 2020 | 6.95M | -6.42M | -48.01% |
| Dec 31, 2019 | 13.38M | 2.79M | 26.41% |
| Dec 31, 2018 | 10.58M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Incyte | 5.36B |
| Jazz Pharmaceuticals | 4.44B |
| Genmab | 3.90B |
| BioMarin Pharmaceutical | 3.24B |
| Exelixis | 2.38B |
| Madrigal Pharmaceuticals | 1.13B |
| Ionis Pharmaceuticals | 1.06B |
| Axsome Therapeutics | 708.24M |
ASND News
- 5 hours ago - Ascendis Pharma price target raised to $345 from $342 at Barclays - TheFly
- 3 days ago - Ascendis Pharma price target lowered to $326 from $330 at Wells Fargo - TheFly
- 3 days ago - Ascendis Pharma reports Q1 adjusted EPS EUR 0.29, consensus EUR (0.15) - TheFly
- 4 days ago - Ascendis Pharma Earnings Call Transcript: Q1 2026 - Transcripts
- 4 days ago - Ascendis Pharma Reports First Quarter 2026 Financial Results - GlobeNewsWire
- 4 days ago - New 2-Year Data from Pivotal ApproaCH Trial of TransCon® CNP (Navepegritide) Show Pronounced Gains in Growth Outcomes in Children with Achondroplasia Aged ≥5 Years - GlobeNewsWire
- 10 days ago - Ascendis to Report First Quarter 2026 Financial Results and Provide Business Update on May 7, 2026 - GlobeNewsWire
- 19 days ago - Ascendis Announces Redemption of All $575 Million of Outstanding 2.25% Convertible Senior Notes Due 2028 - GlobeNewsWire